Jci_page_head_homepage_01 Jci_page_head_homepage_02
Nigel A. Calcutt, Karen L. Allendoerfer, Andrew P. Mizisin, Alicia Middlemas, Jason D. Freshwater, Monica Burgers, Rigel Ranciato, Jean-Dominique Delcroix, Frederick R. Taylor, Renee Shapiro, Kathy Strauch, Henryk Dudek, Thomas M. Engber, Alphonse Galdes, Lee L. Rubin, David R. Tomlinson
Published in Volume 111, Issue 4
J Clin Invest. 2003; 111(4):507–514 doi:10.1172/JCI15792
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 3

SHh-IgG treatment reverses conduction slowing in diabetic rats. MNCV (a) and SNCV (b) measurements were made in the same animals before the onset of diabetes, after 5 weeks of untreated diabetes, and after 5 weeks of thrice weekly treatment with 1 mg/kg of SHh-IgG or vehicle. Data are given as means ± SEM; n = 10–12 per group. Vehicle-treated controls are represented by filled squares, SHh-IgG–treated controls by open squares, vehicle-treated diabetics by filled circles, and SHh-IgG–treated diabetics by open circles. Statistical comparisons between groups were made at the 10-week time point by ANOVA followed by the Student-Newman-Keuls post hoc test. *P < 0.01 for untreated diabetics versus all other groups.